Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Profit After Tax (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Profit After Tax for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 347.99% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.6 million through Dec 2025, down 20.35% year-over-year, with the annual reading at -$4.6 million for FY2025, 20.35% down from the prior year.
  • Profit After Tax hit $1.5 million in Q4 2025 for Eton Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $5.1 million in Q1 2021 to a low of -$9.0 million in Q4 2022.
  • Historically, Profit After Tax has averaged -$1.5 million across 5 years, with a median of -$1.7 million in 2025.
  • Biggest five-year swings in Profit After Tax: plummeted 968.24% in 2022 and later soared 392.62% in 2023.
  • Year by year, Profit After Tax stood at $1.0 million in 2021, then tumbled by 968.24% to -$9.0 million in 2022, then soared by 74.99% to -$2.3 million in 2023, then surged by 73.49% to -$598000.0 in 2024, then soared by 347.99% to $1.5 million in 2025.
  • Business Quant data shows Profit After Tax for ETON at $1.5 million in Q4 2025, -$1.9 million in Q3 2025, and -$2.6 million in Q2 2025.